IDIX Key Stats
|Revenue (Quarterly YoY Growth)||-99.94%|
|EPS Diluted (TTM)||-0.8696|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-116.35M|
|Gross Profit Margin (Quarterly)||21.05%|
|Profit Margin (Quarterly)||-178711%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Gilead's Sofosbuvir Gains FDA Approval, Attracts Patent Battle Fool Dec 10
- Idenix Pharma (IDIX) Reports HCV Treatment Patent Interference (GILD) Street Insider Dec 9
- Update on Gilead's Legal Troubles - Analyst Blog Zacks Dec 4
- IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 2
- Idenix Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) Seeking Alpha Dec 2
- Limited Impact on Gilead (GILD) Expected from Idenix (IDIX) Lawsuit Street Insider Dec 2
- Idenix Pharma (IDIX) Files Two New Patent Suits Against Gilead (GILD) Street Insider Dec 2
- Idenix Pharma (IDIX) Begins Enrollment in HELIX-2 Phase 2 Street Insider Dec 2
- Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection GlobeNewswire Dec 2
- Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences GlobeNewswire Dec 2
IDIX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Idenix Pharmaceuticals is up 1.60% over the last year vs S&P 500 Total Return up 29.87%, Gilead Sciences up 96.20%, and Bristol-Myers Squibb up 62.85%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for IDIX
Pro Report PDF for IDIX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download IDIX Pro Report PDF
Pro Strategies Featuring IDIX
Did Idenix Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.